Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
Abstract
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin’s lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
- Publication:
-
Science
- Pub Date:
- August 2008
- DOI:
- 10.1126/science.1158545
- Bibcode:
- 2008Sci...321..974B
- Keywords:
-
- IMMUNOLOGY